Skip to main content

Chinook Therapeutics, Inc.

KDNYDelisted Aug 11, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001435049

Chinook Therapeutics, Inc. was delisted on Aug 11, 2023; its insiders filed their last Form 4 on Aug 11, 2023; 185 institutions reported holding it in 13F filings for Q2 2023, worth $2.24B in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Chinook Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Chinook Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Chinook Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Bjerkholt EricChief Financial Officer0Aug 11, 20230
Dobmeier EricPresident, CEO0Aug 11, 20230
Griffin Michelle ReneeDirector0Aug 11, 20230
Akkaraju SrinivasDirector0IndirectAug 11, 20230
Greenman William MarinerDirector0Aug 11, 20230
Azelby RobertDirector–Aug 11, 20230
Jerel DavisDirector0IndirectAug 11, 20230
Oxtoby AndrewChief Commercial Officer–Aug 11, 20230
Thomas DolcaDirector0Aug 11, 20230
King Andrew JamesChief Scientific Officer0Aug 11, 20230
Frohlich TomChief Operating Officer0Aug 11, 20230
Krishnan MaheshDirector0Aug 11, 20230
Haghighat RossDirector124,546May 31, 20230
Versant Voyageurs I, L.P.10% Owner0IndirectApr 6, 20220
Versant Voyageurs I Parallel, L.P.10% Owner0IndirectApr 6, 20220
Versant Venture Capital VII, L.P.10% Owner0IndirectApr 6, 20220
Glicklich AlanChief Medical Officer7,891Feb 14, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 1, 2023 (view filing)Aug 1Same dayKing Andrew JamesChief Scientific OfficerSSale−1.17K$39.03−$45.6K−5.7%19.2K after
May 31, 2023 (view filing)May 301 dayGreenman William MarinerDirectorSSale−1.16K$23.30−$26.9K−4.7%23.6K after
Apr 26, 2023 (view filing)5:19 PM ETApr 242 daysDobmeier EricPresident, CEOSSale−23.8K$21.58−$513.5K−7.3%302.3K after
Apr 26, 2023 (view filing)5:19 PM ETApr 242 daysDobmeier EricPresident, CEOSSale+1.20K$22.26+$26.7K+0.4%301.1K after
Apr 19, 2023 (view filing)Apr 172 daysJerel DavisDirectorSSale−295.8K$20.75−$6.14M−40.0%443.7K after
Apr 5, 2023 (view filing)4:43 PM ETApr 32 daysKing Andrew JamesChief Scientific OfficerSSale−5.00K$23.34−$116.7K−22.7%17.0K after10b5-1
Apr 4, 2023 (view filing)Apr 4Same dayKrishnan MaheshDirectorSSale−924$23.01−$21.3K−42.0%1.27K after10b5-1
Mar 3, 2023 (view filing)Mar 12 daysJerel DavisDirectorSSale−400.0K$22.75−$9.10M−65.5%211.0K after3 lots
Feb 15, 2023 (view filing)Feb 105 daysLateBjerkholt EricChief Financial OfficerSSale−857$23.75−$20.4K−2.2%38.9K after
Feb 15, 2023 (view filing)Feb 105 daysLateDobmeier EricPresident, CEOSSale−8.10K$23.75−$192.3K−2.6%301.1K after
Feb 15, 2023 (view filing)Feb 105 daysLateFrohlich TomChief Operating OfficerSSale−3.70K$23.75−$87.9K−2.4%150.8K after
Feb 15, 2023 (view filing)Feb 105 daysLateKing Andrew JamesChief Scientific OfficerSSale−2.39K$23.75−$56.8K−10.9%19.5K after
Feb 2, 2023 (view filing)Jan 312 daysFrohlich TomChief Operating OfficerSSale−4.57K$24.68−$112.7K−3.0%147.7K after
Feb 2, 2023 (view filing)Jan 312 daysBjerkholt EricChief Financial OfficerSSale−2.89K$24.68−$71.3K−7.2%37.3K after
Feb 2, 2023 (view filing)Jan 312 daysKing Andrew JamesChief Scientific OfficerSSale−3.24K$24.68−$80.1K−17.7%15.1K after
Feb 1, 2023 (view filing)8:32 PM ETJan 30-312 daysDobmeier EricPresident, CEOSSale−32.7K$24.58−$803.4K−10.2%289.0K after2 lots
Jan 4, 2023 (view filing)7:44 PM ETJan 31 dayKing Andrew JamesChief Scientific OfficerSSale−10.0K$25.82−$258.2K−50.0%9.99K after
Dec 15, 2022 (view filing)4:28 PM ETDec 132 daysFrohlich TomChief Operating OfficerSSale−10.0K$25.00−$250.0K−6.5%143.9K after
Dec 2, 2022 (view filing)4:26 PM ETDec 11 dayDobmeier EricPresident, CEOSSale−30.0K$22.31−$669.4K−11.0%241.7K after
Dec 2, 2022 (view filing)Dec 11 dayBjerkholt EricChief Financial OfficerSSale−5.77K$22.29−$128.6K−14.9%32.8K after
Nov 9, 2022 (view filing)4:21 PM ETNov 72 daysFrohlich TomChief Operating OfficerSSale−10.0K$22.16−$221.6K−6.5%143.9K after
Oct 11, 2022 (view filing)Oct 65 daysFrohlich TomChief Operating OfficerSSale−7.36K$19.69−$144.9K−4.9%143.9K after
Oct 11, 2022 (view filing)Oct 65 daysKing Andrew JamesChief Scientific OfficerSSale−3.56K$19.69−$70.0K−22.2%12.5K after
Sep 6, 2022 (view filing)Sep 24 daysThomas DolcaDirectorPPurchase+10.0K$21.22+$212.2KNew position10.0K after2 lots
Aug 5, 2022 (view filing)5:09 PM ETAug 41 dayKing Andrew JamesChief Scientific OfficerSSale−5.00K$20.00−$100.0K−45.9%5.90K after
Jul 13, 2022 (view filing)4:11 PM ETJul 112 daysKing Andrew JamesChief Scientific OfficerSSale−5.00K$18.09−$90.5K−45.9%5.90K after
Jun 1, 2022 (view filing)May 275 daysAkkaraju SrinivasDirectorPPurchase+570.0K$14.00+$7.98M+12.4%5.16M after
May 27, 2022 (view filing)May 252 daysDobmeier EricPresident, CEOPPurchase+5.00K$13.03+$65.2K+2.5%205.9K after
Apr 13, 2022 (view filing)5:34 PM ETApr 112 daysKing Andrew JamesChief Scientific OfficerSSale−5.00K$15.36−$76.8K−45.9%5.90K after
Feb 23, 2022 (view filing)Feb 185 daysKing Andrew JamesChief Scientific OfficerSSale−2.50K$13.00−$32.5K−29.8%5.90K after
Feb 14, 2022 (view filing)Feb 113 daysBjerkholt EricChief Financial OfficerSSale−895$12.74−$11.4K−3.9%22.2K after
Feb 14, 2022 (view filing)Feb 113 daysKing Andrew JamesChief Scientific OfficerSSale−2.50K$12.74−$31.8K−22.9%8.40K after
Feb 14, 2022 (view filing)Feb 113 daysGlicklich AlanChief Medical OfficerSSale−2.39K$12.74−$30.5K−23.3%7.89K after
Feb 14, 2022 (view filing)Feb 113 daysFrohlich TomChief Operating OfficerSSale−3.73K$12.74−$47.6K−2.6%137.7K after
Feb 11, 2022 (view filing)5:26 PM ETFeb 101 dayKing Andrew JamesChief Scientific OfficerSSale−2.50K$13.31−$33.3K−37.9%4.09K after
Jan 5, 2022 (view filing)5:16 PM ETJan 32 daysVersant Voyageurs I, L.P. and 2 others10% OwnerSSale−600.0K$16.00−$9.60M−14.2%3.62M after
Jan 5, 2022 (view filing)5:16 PM ETJan 32 daysVersant Voyageurs I, L.P. and 2 others10% OwnerSSale−400.0K$16.00−$6.40M−42.0%552.1K after2 lots
Jan 5, 2022 (view filing)Jan 32 daysJerel DavisDirector, 10% OwnerSSale−1.00M$16.00−$16.0M−64.4%552.1K afterFrom original3 lots
Nov 17, 2021 (view filing)Nov 152 daysAkkaraju SrinivasDirectorPPurchase+1.22M$14.00+$17.0M+36.0%4.59M after
Nov 12, 2021 (view filing)7:59 PM ETNov 93 daysKing Andrew JamesChief Scientific OfficerSSale−5.00K$13.53−$67.7K−55.0%4.09K after
Nov 12, 2021 (view filing)Nov 102 daysFrohlich TomChief Operating OfficerSSale−6.23K$15.48−$96.4K−4.4%134.6K after
Nov 9, 2021 (view filing)9:40 PM ETNov 5-84 daysFrohlich TomChief Operating OfficerSSale−33.8K$14.48−$488.9K−19.3%140.8K after3 lots
Sep 24, 2021 (view filing)Sep 24Same dayFrohlich TomChief Operating OfficerSSale−20.0K$13.00−$260.0K−13.0%133.4K after
Sep 22, 2021 (view filing)Sep 202 daysDobmeier EricPresident, CEOPPurchase+2.00K$12.00+$24.0K+1.9%109.8K after
Aug 31, 2021 (view filing)7:06 PM ETAug 274 daysVersant Voyageurs I, L.P. and 2 others10% OwnerSSale−510.0K$14.00−$7.14M−10.8%4.22M after
Aug 31, 2021 (view filing)7:06 PM ETAug 274 daysVersant Voyageurs I, L.P. and 2 others10% OwnerSSale−340.0K$14.00−$4.76M−34.5%644.1K after2 lots
Aug 31, 2021 (view filing)Aug 274 daysJerel DavisDirector, 10% OwnerSSale−850.0K$14.00−$11.9M−56.9%644.1K after3 lots
Aug 20, 2021 (view filing)Aug 182 daysAkkaraju SrinivasDirectorPPurchase+208.5K$11.98+$2.50M+6.6%3.38M after
Aug 19, 2021 (view filing)Aug 18-191 dayDobmeier EricPresident, CEOPPurchase+10.0K$11.82+$118.2K+10.2%107.8K after2 lots